Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, progressive chronic inflammation of a single cerebral hemisphere that usually affects children. It is characterized by severe seizures, loss of motor skills and speech, hemiparesis, and dementia.
Biomarker and diagnostic research for Rasmussen subacute encephalitis has been reported in the published literature.
No approved treatments are currently available for Rasmussen subacute encephalitis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Rasmussen subacute encephalitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Rasmussen subacute encephalitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
58 publications have been identified in PubMed for Rasmussen subacute encephalitis. Research spans Case Report / Case Series (34%), Basic Science / Preclinical (22%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 20 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Rasmussen subacute encephalitis
Designated
Exclusivity End |
|---|
Designation Status |
|---|
rituximab | rituximab | Keck Graduate Institute of Applied Life Sciences | 2016 | — | Designated |
2 trials found
34%
Laboratory research | 13 | 22% |
Research summaries | 9 | 16% |
Clinical study results | 7 | 12% |
Disease patterns and progression | 6 | 10% |
Testing and diagnosis research | 2 | 3% |
Other research | 1 | 2% |
Stredny CM (2026). [PMID: 42029183](https://pubmed.ncbi.nlm.nih.gov/42029183/). *Epilepsia*. [Review / Meta-Analysis]
A ZA (2026). [PMID: 42043578](https://pubmed.ncbi.nlm.nih.gov/42043578/). *Childs Nerv Syst*. [Basic Science / Preclinical]
Quinones-Valdez G (2026). [PMID: 42129303](https://pubmed.ncbi.nlm.nih.gov/42129303/). *Sci Rep*. [Basic Science / Preclinical]
Evers Smith C (2026). [PMID: 41702141](https://pubmed.ncbi.nlm.nih.gov/41702141/). *Journal of neuroimmunology*. [Case Report / Case Series]
Gélisse P (2026). [PMID: 42232090](https://pubmed.ncbi.nlm.nih.gov/42232090/). *Epilepsy Behav Rep*. [Case Report / Case Series]
Zafar H (2026). [PMID: 41604092](https://pubmed.ncbi.nlm.nih.gov/41604092/). *Acta neurologica Belgica*. [Clinical Trial Publication]
Cantarín-Extremera V (2026). [PMID: 42057109](https://pubmed.ncbi.nlm.nih.gov/42057109/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Liu Y (2026). [PMID: 41874285](https://pubmed.ncbi.nlm.nih.gov/41874285/). *Epilepsia*. [Epidemiology / Natural History]
Alshurem M (2026). [PMID: 41768762](https://pubmed.ncbi.nlm.nih.gov/41768762/). *International medical case reports journal*. [Case Report / Case Series]
Fu C (2026). [PMID: 41928687](https://pubmed.ncbi.nlm.nih.gov/41928687/). *Epilepsia*. [Basic Science / Preclinical]
AI-curated news mentioning Rasmussen subacute encephalitis
Updated Sep 8, 2026
A recent study published in PubMed explores the electroclinical and neuroradiological evolution in patients with Rasmussen encephalitis. The findings provide insights into the disease's progression in both pediatric and adult populations.
New research identifies centroparietal periodic sharp-wave discharges and biphasic complexes as potential EEG biomarkers for the early diagnosis of Rasmussen encephalitis. This discovery could enhance diagnostic accuracy and improve patient outcomes.
A recent study published in PubMed explores the immune landscape of the brain in patients with Rasmussen encephalitis. This research provides insights into the immune mechanisms involved in this rare neurological disorder.